Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of YHD1044 in premature ejaculation

Phase 1/Phase 2

Yuhan Corporation